The market grossly overreacted to Amarin's sizable capital raise last week. Here's why.
These three healthcare stocks are worth checking out right now. Here's why.
Tilray's longer-term outlook remains murky.
CRISPR Therapeutics and Curaleaf Holdings could have a lot more room to run.
Shareholders are none too pleased with Inovio's cost-cutting initiative. Here's why.
Amarin and Heron Therapeutics could turn out to be outstanding bargains.
These three medtech companies are at the forefront of diabetes care.
Gilead Sciences decided to inject $5.1 billion into its R&D partner Galapagos NV over the weekend.
Marijuana investors might want to keep an eye on these three pot stocks in July.
Walgreens' shares perked up last month following an upbeat third-quarter earnings report.
Here's why investors shouldn't fret about Canopy's managerial turnover.
Atara's shares have collapsed this year. Here's why.
Investors were none too pleased with the robotic surgery specialist's first-quarter earnings report.
Geron's stock has rebounded nicely in the first half of 2019.
Biogen's swing and miss in Alzheimer's disease has weighed on its shares this year.
Wall Street clearly isn't pleased with Bristol's acquisition of Celgene.
The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.
The biotech's shares perked up for two unrelated reasons last month.
AbbVie's stock has been hit hard by Humira's loss of exclusivity in Europe and the biotech's megamerger with Allergan.
Amicus' shares shot up by 10.7% last month. Here's why.